Shots:
- Gilead to acquire Ouro for a total of $1,675M in upfront cash & up to $500M in contingent milestone payments. Acquisition will add Ouro’s P-I/II asset OM336 (gamgertamig) to Gilead’s inflammation portfolio, with registrational studies to begin in 2027
- Also, Gilead is in advanced discussions with Galapagos for a potential R&D collaboration on the acquired Ouro’s assets, under which Galapagos would fund 50% of upfront & 50% of any milestone payments, & absorb most of Ouro’s operating assets
- Companies would co-develop OM336, with Galapagos leading early development costs & sharing registrational study expenses equally, while Gilead retains global commercialization rights (ex-Greater China) & pays 20–23% royalties to Galapagos
Ref: Businesswire| Image: Ouro Medicine | Press Release
Related News: Gilead Sciences to Acquire Arcellx for $7.8B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
